Biomarkers of Alzheimer's disease: The present and the future |
| |
Authors: | S Lehmann C Delaby J Touchon C Hirtz A Gabelle |
| |
Institution: | 1. Laboratoire de biochimie protéomique clinique et CCBHM, hôpital Saint-Éloi, institut de recherche en biothérapie, CHU de Montpellier, 80, avenue A.-Fliche, 34295 Montpellier cedex 5, France;2. Inserm U1040, université Montpellier 1, 80, avenue A.-Fliche, 34295 Montpellier cedex 5, France;3. Centre Mémoire Ressources Recherche, université Montpellier I, hôpital Gui-de-Chauliac, CHU de Montpellier, 80, avenue A.-Fliche, 34295 Montpellier cedex 5, France |
| |
Abstract: | A paradigm shift has occurred in the last ten years in the diagnostic field of Alzheimer's disease (AD). Scientific thought has enriched the concept of AD as a pathophysiological continuum and emphasized contribution of biological, morphological and functional brain imaging biomarkers for diagnosis, in particular during the early stages of the disease. We address here the present and the future of these biological biomarkers. Most of them are linked to the pathophysiological lesions of the Alzheimer process: aggregates of hyperphosphorylated tau proteins, also called neurofibrillary tangles (NFT), and extracellular deposit of amyloid-beta peptides (Aβ), also called senile plaques. The detection in the cerebrospinal fluid (CSF) of tau and Aβ represents the current diagnostic practice of AD. Improvement for a more accurate and earlier biological diagnosis is however expected using a new generation of biomarkers, mostly in relation with tau and Aβ metabolism. |
| |
Keywords: | Alzheimer's disease Diagnosis Biomarkers Tau protein β-amyloid peptides |
本文献已被 ScienceDirect 等数据库收录! |
|